Pay in 4 interest-free payments of $7.35 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Tirzepatide (Dual Receptor) Mounjaro FDA-approved for type 2 diabetes Zepbound FDA-approved for obesity Tirzepatide activates two receptors: GLP-1 and GIP
Cap colour subject to change.
Exciting experimental evidence available in patients with NASH suggests the potential of LG to reduce lipotoxicity by improving adipose tissues insulin sensitivities (129)
Tirzepatide is a dual agonist, working on both GLP-1 and GIP receptors, which produces larger average weight loss in head-to-head trials
Yes, especially strength training
US$ 24.45
US$ 29.12
US$ 23.75
